NCT00829049View on ClinicalTrials.gov

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

PHASE4TerminatedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Acne Vulgaris
Interventions
DRUG

Tazarotene Cream 0.1%

1 pea-size amount, QD x 16 weeks

DRUG

Adapalene

1 pea-size amount, QD x 16 weeks

Trial Locations (1)

Unknown

Fremont

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY